Table 1 Patient characteristics, transplantation rate and latency period of xenografts

From: Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer

Characteristics No. of patients (%) Latency period (days) P Transplantation rate (%) P
Gender    0.5   0.92
 Male 133 (71.2%) 67.05 ± 34.40   33.8% (45/133)  
 Female 52 (28.1%) 63.00 ± 29.52   34.6% (18/52)  
Age (years)    0.672   0.724
 ≤45 25 (13.5%) 73.88 ± 32.16   32.0% (8/25)  
 45–60 69 (37.3%) 67.17 ± 31.55   37.7% (26/69)  
 ≥60 91 (49.2%) 62.37 ± 34.78   31.9% (29/91)  
Stage    0.682   0.827
 I/II 5 (27.0%) 47.5 ± 14.85   40.0% (2/5)  
 III/IV 173 (93.5%) 67.16 ± 33.13   35.3% (61/173)  
 NA 7 (37.8%) 57   14.3% (1/7)  
Primary site    0.893   0.653
 Upper 52 (28.1%) 63.18 ± 29.90   38.5 (20/52)  
 Middle 62 (33.5%) 70.24 ± 35.86   35.5 (22/62)  
 Lower 65 (33.1%) 63.16 ± 33.96   30.8 (20/65)  
 Anastomosis 6 (32.4%) 71   16.7 (1/6)  
Differentiation    0.18   0.212
 High 3 (1.6%) 13   33.3 (1/3)  
 Moderate 59 (31.9%) 59.36 ± 31.15   42.4 (25/59)  
 Moderate-poor 42 (22.7%) 67.27 ± 29.82   38.1 (16/42)  
 Poor 81 (43.8%) 74.60 ± 35.07   25.9 (21/81)  
Lauren classification    0.277   0.291
 Intestinal 89 (48.1%) 59.58 ± 30.76   39.3% (35/89)  
 Diffuse 79 (42.7%) 74.43 ± 34.19   27.8% (22/79)  
 Mixed 17 (9.2%) 68.33 ± 37.16   35.3% (6/17)  
HER2 expression    0.385   0.603
 Negative 145 (78.4%) 61.27 ± 28.15   33.1% (48/145)  
 Positive 40 (21.6%) 68.20 ± 34.43   37.5% (15/40)  
Chemotherapy    0.505   0.000
 Before 71 (38.4%) 67.85 ± 34.33   52.1% (37/71)  
 After 114 (61.6%) 63.30 ± 31.77 0.782 22.8% (26/114) 0.6
  Partial response 21 (18.4%) 73.14 ± 35.81   33.3% (7/21)  
  Stable disease 39 (34.2%) 62.67 ± 20.91   17.9% (7/39)  
  Progressive Disease 49 (43.0%) 56.80 ± 35.32   22.4% (11/49)  
  NA 5 (4.4%) 57   20.0% (1/5)  
  1. Note: NA, non-available. Data represent mean ± s.d. P calculated by chi-square test, unpaired two-tailed t-test or one-way analysis of variance separately.